peptide-receptor radionuclide therapy
June 24, 2019
Nuclear Medicine Therapy Shows Long-Term Effectiveness for Malignant Neuroendocrine Tumors BookmarkGeorge Lundberg, MD
Excerpt from the Society of Nuclear Medicine and Molecular Imaging:
“A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study is featured in the April issue of The Journal of Nuclear Medicine.
“While PRRT has been used for more than 20 years to treat patients with inoperable or metastatic somatostatin receptor–positive tumors, knowledge of long-term outcomes has been limited. A number of clinical studies have demonstrated PRRT’s efficacy, and the overall response rate (including complete response, partial response, minor response, and stable disease) is about 70-80 percent for the two most commonly used radiopharmaceuticals: yttrium-90 (90Y)-DOTATOC (best suited for treating larger tumors) and lutetium-177 (177Lu)-DOTATATE (preferred for smaller tumors). For patients who respond to PRRT, the prognosis is generally favorable, with a median time to disease progression of three to four years.”
Go to full article published by the Society of Nuclear Medicine and Molecular Imaging on April 26, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.